BIOCRYST PHARMACEUTICALS INC — Director's Dealing 2014

May 28, 2014

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: BIOCRYST PHARMACEUTICALS INC (BCRX)
CIK: 0000882796
Period of Report: 2014-05-26

Reporting Person: Barnes Alane P (VP, General Counsel & Corp Sec)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2014-05-26	Emp. Stock Option (Right to Buy)	$5.45	A	17000	Acquired	2023-08-08	Common Stock (17000)	Direct

Footnotes

F1: On May 26, 2014, the Board of Directors determined that the BCX4161 OPuS-1 clinical trial met its goals and BCX4161 warrants further development. As a result, one of the vesting criteria associated with the performance-based stock options awarded to all employees in August 2013 has been met. Therefore, 25% of the performance-based stock options vested on May 26, 2014.